{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:03:17Z","timestamp":1772114597512,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province","award":["20240043"],"award-info":[{"award-number":["20240043"]}]},{"DOI":"10.13039\/501100014988","name":"Program for the Scientific Activities of Selected Returned Overseas Professionals in Shaanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014988","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003398","name":"Shanxi Scholarship Council of China","doi-asserted-by":"publisher","award":["2023-187"],"award-info":[{"award-number":["2023-187"]}],"id":[{"id":"10.13039\/501100003398","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.seminoncol.2025.152373","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T21:24:51Z","timestamp":1750886691000},"page":"152373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Peripheral blood CD4+CD25+ T lymphocytes and TGF-\u03b2 predict the prognosis in relapsed\/refractory multiple myeloma treated with daratumumab"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6065-2609","authenticated-orcid":false,"given":"Hanyue","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.seminoncol.2025.152373_bib0001","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.soncn.2017.05.012","article-title":"Pathobiology and diagnosis of multiple myeloma","volume":"33","author":"Brigle","year":"2017","journal-title":"Semin Oncol Nurs"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152373_bib0002","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"De Weers","year":"2011","journal-title":"J Immunol (Baltim Md: 1950)"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152373_bib0003","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/hematology.2023000444","article-title":"Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line","volume":"2023","author":"Hartley-Brown","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152373_bib0004","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.7150\/ijbs.68148","article-title":"Regulation of CD38 on multiple myeloma and NK cells by monoclonal antibodies","volume":"18","author":"Wu","year":"2022","journal-title":"Int J Biol Sci"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152373_bib0005","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seminoncol.2025.152373_bib0006","first-page":"10","article-title":"Targeting TGF-\u03b2 signaling in the multiple myeloma microenvironment: steering CARs and T cells in the right direction","author":"Rana","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152373_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052259","article-title":"Oncolytic virotherapy and microenvironment in Multiple myeloma","volume":"22","author":"Marchica","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152373_bib0008","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092018","article-title":"Overcoming the immunosuppressive tumor microenvironment in Multiple myeloma","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.seminoncol.2025.152373_bib0009","first-page":"554","article-title":"Luteolin inhibits the TGF-\u03b2 signaling pathway to overcome bortezomib resistance in multiple myeloma","author":"Li","year":"2023","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152373_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","article-title":"Overcoming tgf\u03b2-mediated immune evasion in cancer","volume":"22","author":"Tauriello","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.seminoncol.2025.152373_bib0011","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152373_bib0012","first-page":"480","article-title":"Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)","volume":"61","author":"Chinese Hematology Association, Chinese Society of Hematology","year":"2022","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152373_bib0013","doi-asserted-by":"crossref","DOI":"10.1186\/s40001-022-00923-5","article-title":"PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed\/refractory multiple myeloma patients","volume":"27","author":"Chen","year":"2022","journal-title":"Eur J Med Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152373_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152373_bib0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01019-5","article-title":"A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death","volume":"14","author":"Ray","year":"2024","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152373_bib0016","first-page":"260","article-title":"[Progress in the treatment of multiple myeloma with daratumumab]","volume":"42","author":"Lu","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152373_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9041195","article-title":"Resistance mechanisms towards CD38-directed antibody therapy in multiple myeloma","volume":"9","author":"Franssen","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.seminoncol.2025.152373_bib0018","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 Antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"Van de Donk","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152373_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10060194","article-title":"TGF-\u03b2 in T cell biology: implications for cancer immunotherapy","volume":"10","author":"Dahmani","year":"2018","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.seminoncol.2025.152373_bib0020","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/cyto.a.23724","article-title":"Comprehensive phenotyping of T cells using flow cytometry","volume":"95","author":"Mousset","year":"2019","journal-title":"Cytom A"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152373_bib0021","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152373_bib0022","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5152\/tjh.2011.26","article-title":"The correlation between T regulatory cells and autologous peripheral blood stem cell transplantation in multiple myeloma","volume":"28","author":"Er\u00e7etin","year":"2011","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.seminoncol.2025.152373_bib0023","first-page":"13","article-title":"Armored BCMA CAR T cells eliminate multiple myeloma and are resistant to the suppressive effects of TGF-\u03b2","author":"Alabanza","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152373_bib0024","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/14728222.2020.1744568","article-title":"TGF-beta: a master immune regulator","volume":"24","author":"Larson","year":"2020","journal-title":"Expert Opin Ther Targets"},{"issue":"11","key":"10.1016\/j.seminoncol.2025.152373_bib0025","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1631\/jzus.B2200277","article-title":"High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma","volume":"23","author":"Yue","year":"2022","journal-title":"J Zhejiang Univ-SCI B"},{"issue":"2","key":"10.1016\/j.seminoncol.2025.152373_bib0026","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1248\/bpb.b21-00966","article-title":"TGF-\u03b2 and cancer immunotherapy","volume":"45","author":"Maruyama","year":"2022","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152373_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041200","article-title":"Metabolic features of multiple myeloma","volume":"19","author":"El Arfani","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152373_bib0028","first-page":"996","article-title":"Expression analysis of CD4+CD25+\/highCD127lowTregs and TGF-\u03b2 in peripheral blood of patients with multiple myeloma[J]","author":"Wenmin","year":"2008","journal-title":"J Cell Mol Immunol"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152373_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015150","article-title":"Characterization of protective human CD4CD25 FOXP3 regulatory T cells generated with IL-2, TGF-\u03b2 and retinoic acid","volume":"5","author":"Lu","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152373_bib0030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152373_bib0031","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.seminoncol.2025.152373_bib0032","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.seminoncol.2025.152373_bib0033","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ejh.13840","article-title":"Treatment horizon in multiple myeloma","volume":"109","author":"Soekojo","year":"2022","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.seminoncol.2025.152373_bib0034","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.seminoncol.2025.152373_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6084012","article-title":"Monoclonal antibody therapies in multiple myeloma: a challenge to develop novel targets","volume":"2019","author":"Nishida","year":"2019","journal-title":"J Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377542500065X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377542500065X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T02:12:25Z","timestamp":1750990345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009377542500065X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S009377542500065X"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152373","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral blood CD4+CD25+ T lymphocytes and TGF-\u03b2 predict the prognosis in relapsed\/refractory multiple myeloma treated with daratumumab","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152373"}}